Feds Keep Marijuana Tests for Workers Despite Trump Reclassification Order

Why It Matters

Employers must maintain current drug‑testing policies, as federal rescheduling could reshape legal obligations and disability‑law considerations. The divergence between federal rules and state protections creates ongoing risk for multinational workforces.

Key Takeaways

• HHS keeps marijuana metabolites in federal testing panels
• Trump’s order to reschedule marijuana not yet implemented
• Marijuana remains Schedule I under federal law
• State laws vary on employee protections for cannabis use
• Employers must retain drug policies for regulated workers

Pulse Analysis

Federal drug‑testing guidance remains unchanged, signaling that the Department of Health and Human Services is waiting for concrete legislative action before altering its panels. While President Trump’s executive order urged a swift reclassification of cannabis to Schedule III, the agency’s latest Federal Register notice underscores the legal inertia that still categorizes marijuana as a Schedule I drug. This disconnect means that federal contractors, transportation‑regulated employees, and other federally‑mandated workforces will continue to face mandatory marijuana testing, preserving the status quo for compliance teams.

State‑level reforms have accelerated the cultural acceptance of cannabis, with more than two dozen states legalizing adult recreational use. However, each jurisdiction crafts its own employee‑rights framework, ranging from Colorado’s permissive stance—allowing employers to act on positive tests—to Illinois’ protective measures that shield off‑duty users from adverse actions. HR leaders must navigate this patchwork, aligning federal obligations with state‑specific anti‑discrimination statutes while managing the risk of on‑the‑job impairment. The divergent legal landscape forces companies to adopt nuanced policies that respect local protections without compromising federal compliance.

Looking ahead, any shift in federal scheduling could ripple through the Americans with Disabilities Act and other labor regulations, potentially redefining employer liability for medical cannabis users. Until Congress or the DEA formalizes a reschedule, businesses are advised to retain clear drug‑testing protocols, especially for safety‑critical roles, and to monitor state legislative trends closely. Proactive communication, consistent policy enforcement, and legal counsel engagement will be essential for mitigating exposure as the regulatory environment evolves.